Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Benfotiamine upregulates antioxidative system in activated BV-2 microglia cells.

Bozic I, Savic D, Stevanovic I, Pekovic S, Nedeljkovic N, Lavrnja I.

Front Cell Neurosci. 2015 Sep 4;9:351. doi: 10.3389/fncel.2015.00351.

2.

Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets.

Toth-Manikowski S, Atta MG.

J Diabetes Res. 2015;2015:697010. doi: 10.1155/2015/697010. Review.

3.

Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells.

Sugimori N, Espinoza JL, Trung LQ, Takami A, Kondo Y, An DT, Sasaki M, Wakayama T, Nakao S.

PLoS One. 2015 Apr 7;10(4):e0120709. doi: 10.1371/journal.pone.0120709.

4.

Antioxidant strategies in the management of diabetic neuropathy.

Oyenihi AB, Ayeleso AO, Mukwevho E, Masola B.

Biomed Res Int. 2015;2015:515042. doi: 10.1155/2015/515042. Review.

5.

Benfotiamine attenuates inflammatory response in LPS stimulated BV-2 microglia.

Bozic I, Savic D, Laketa D, Bjelobaba I, Milenkovic I, Pekovic S, Nedeljkovic N, Lavrnja I.

PLoS One. 2015 Feb 19;10(2):e0118372. doi: 10.1371/journal.pone.0118372.

6.

Neurodegeneration in diabetic retina and its potential drug targets.

Ola MS, Alhomida AS.

Curr Neuropharmacol. 2014 Jul;12(4):380-6. doi: 10.2174/1570159X12666140619205024.

7.

Preventive effects of benfotiamine in chronic diabetic complications.

Chakrabarti R, Chen M, Liu W, Chen S.

J Diabetes Investig. 2011 Apr 7;2(2):123-31. doi: 10.1111/j.2040-1124.2010.00077.x.

8.

Novel drugs and their targets in the potential treatment of diabetic retinopathy.

Nawaz MI, Abouammoh M, Khan HA, Alhomida AS, Alfaran MF, Ola MS.

Med Sci Monit. 2013 Apr 26;19:300-8. doi: 10.12659/MSM.883895. Review.

9.

Prostatic acid phosphatase is required for the antinociceptive effects of thiamine and benfotiamine.

Hurt JK, Coleman JL, Fitzpatrick BJ, Taylor-Blake B, Bridges AS, Vihko P, Zylka MJ.

PLoS One. 2012;7(10):e48562. doi: 10.1371/journal.pone.0048562.

10.

Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Farmer KL, Li C, Dobrowsky RT.

Pharmacol Rev. 2012 Oct;64(4):880-900. doi: 10.1124/pr.111.005314. Review.

11.

Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications.

Nagai R, Murray DB, Metz TO, Baynes JW.

Diabetes. 2012 Mar;61(3):549-59. doi: 10.2337/db11-1120. Review.

12.

Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects.

Smithline HA, Donnino M, Greenblatt DJ.

BMC Clin Pharmacol. 2012 Feb 4;12:4. doi: 10.1186/1472-6904-12-4.

13.

Genomic damage in endstage renal disease-contribution of uremic toxins.

Schupp N, Heidland A, Stopper H.

Toxins (Basel). 2010 Oct;2(10):2340-58. doi: 10.3390/toxins2102340. Review.

14.

Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages.

Shoeb M, Ramana KV.

Free Radic Biol Med. 2012 Jan 1;52(1):182-90. doi: 10.1016/j.freeradbiomed.2011.10.444.

15.

Benfotiamine increases glucose oxidation and downregulates NADPH oxidase 4 expression in cultured human myotubes exposed to both normal and high glucose concentrations.

Fraser DA, Hessvik NP, Nikolić N, Aas V, Hanssen KF, Bøhn SK, Thoresen GH, Rustan AC.

Genes Nutr. 2012 Jul;7(3):459-69. doi: 10.1007/s12263-011-0252-8.

16.

Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease.

Kim TH, Lee JY, Park JS, Park SW, Jang AS, Lee JY, Byun JY, Uh ST, Koh ES, Chung IY, Park CS.

PLoS One. 2011;6(8):e22711. doi: 10.1371/journal.pone.0022711.

Items per page

Supplemental Content

Support Center